June 16 (Reuters) - Advanced lung cancer patients who took
Merck & Co's Keytruda immuno-oncology medicine in a
large trial and were previously untreated went longer without
their disease worsening and showed a survival advantage over
those given standard chemotherapy, the drugmaker said on
Thursday.
Read more
No comments:
Post a Comment